2021 annual financial data
Immunovant 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was Not calculable.
Operating income was -108,117,000 USD and net income was -107,431,000 USD.
Operating cash flow was -83,327,000 USD.
Get free Immunovant email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -108,117,000 USD
- Net income
- -107,431,000 USD
- Operating cash flow
- -83,327,000 USD